TMAN.BK T Man Pharmaceutical PCL
- Market cap
- THB 4.08B
- P/E
- 8.0x
- P/B
- 1.85x
- ROE
- 19.3%
- Dividend yield
- 4.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is TMAN.BK undervalued?
Graham numberTMAN.BK trades 18.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
T Man Pharmaceutical PCL fundamental analysis
No fundamental analysis for T Man Pharmaceutical PCL yet.
T Man Pharmaceutical PCL stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About T Man Pharmaceutical PCL
T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties' Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatolog…
Full company profileT Man Pharmaceutical PCL financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
T Man Pharmaceutical PCL annual financial statements (THB; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.02B | 1.97B | 2.21B | 2.51B | 2.44B |
| Gross Profit | 1.09B | 969M | 1.08B | 1.17B | 1.12B |
| Operating Income | 600M | 517M | 537M | 565M | 525M |
| EBITDA | 683M | 623M | 655M | 768M | 682M |
| Net Income | 473M | 431M | 451M | 523M | 424M |
| EPS | 1.18 | 1.08 | 1.13 | 1.31 | 1.06 |
| Balance Sheet | |||||
| Total Assets | 2.28B | 2.63B | 3.46B | 3.78B | 3.87B |
| Total Liabilities | 1.24B | 1.11B | 1.69B | 1.67B | 1.67B |
| Shareholders' Equity | 1.04B | 1.52B | 1.77B | 2.12B | 2.20B |
| Cash & Short-term Investments | 307M | 348M | 448M | 399M | 502M |
| Cash Flow | |||||
| Operating Cash Flow | 524M | 282M | 520M | 336M | 715M |
| Capital Expenditure | 235M | 220M | 174M | 226M | 305M |
| Free Cash Flow | 289M | 62.1M | 346M | 110M | 410M |
| Ratios | |||||
| ROE | 45.4% | 28.4% | 25.5% | 24.7% | 19.3% |
| ROA | 20.8% | 16.4% | 13.0% | 13.8% | 11.0% |
| Net Profit Margin | 23.4% | 21.9% | 20.4% | 20.9% | 17.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
T Man Pharmaceutical PCL dividends
- Dividend yield
- 4.31%
- Forward dividend
- 0.56 THB
- Payout ratio
- 33.6%
- Ex-dividend date
- Aug 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | THB 176M | 0.44 | 33.6% |
| 2024 | THB 1.34B | 3.34 | 296.3% |
| 2023 | THB 11.8M | 0.03 | 2.7% |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns T Man Pharmaceutical PCL
- Insiders 83.31%
- Institutions 0.08%
- Public & others 16.61%
- Shares outstanding 400M
- Free float 86.5M
T Man Pharmaceutical PCL company profile
- Company name
- T Man Pharmaceutical PCL
- Ticker
- TMAN.BK
- Exchange
- Thailand Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- 69/1 Soi Bang Khun Thian 14, Bangkok, Thailand, 10150
- Phone
- 66 2 415 1007
- Website
- tmanpharmaceutical.com
About T Man Pharmaceutical PCL
T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties' Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and traditional medicines, dietary supplements, vitamins and minerals, skin care and aesthetics, whey protein, and mommy and kid products, as well as cosmetics, modern medicines, mossi guard, nevtral, propolis, and vita-c products. In addition, it offers products under various brand names, such as Iyara, Propoliz, POLAR, and Fibermate. Further, the company offers original equipment manufacturing services. Additionally, it offers medicines in the form of tablets, capsules, powders, liquids, and semisolids. The company also exports its products. T.Man Pharmaceutical Public Company Limited was founded in 1991 and is based in Bangkok, Thailand.
T Man Pharmaceutical PCL management
10- Mr. Prapon ThanachotipanCEO, Acting Chief Sales Officer, Acting Chief Marketing Officer & Director · born 1982
- Ms. Orapan ThanachotipanDeputy CEO of Financial, Accounting & Administration & Director · born 1981
- Ms. Benjawan ThanachotipanDeputy CEO of International Sales and Director · born 1987
- Ms. Siriwan ThanachotipanDeputy Chief Executive Officer of Research & Development and Director · born 1984
- Ms. Darika TaengtrongCFO & Company Secretary · born 1983
- Mr. Tras ObsuwanCOO & Head of Investor Relation · born 1987
- Mr. Bordin ThumacheewanskulCompliance Officer · born 1989
- Mr. Wattana ChannakhinHead of Internal Audit · born 1979
- Ms. Pempichanan ThanachotipanChief Procurement Officer · born 1985
- Mr. Varitthorn SiripraphatmongkhonChief Engineering Officer · born 1984